

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/625,164	07/23/2003	Eddie Reed	27497/2002	8006
29932	7590 10/20/2005		EXAMINER	
PALMER & DODGE, LLP PAULA CAMPBELL EVANS			HOEKSTRA, JEFFREY GERBEN	
	GTON AVENUE		ART UNIT	PAPER NUMBER
BOSTON, MA 02199			3736	

DATE MAILED: 10/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

·		Application No.	Applicant(s)			
Office Action Summary		10/625,164	REED ET AL.			
		Examiner	Art Unit			
		Jeffrey G. Hoekstra	3736			
Period fo	The MAILING DATE of this communication apor Reply	pears on the cover sheet with the c	orrespondence address			
WHI(- Exte after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPI CHEVER IS LONGER, FROM THE MAILING I ensions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statu- reply received by the Office later than three months after the mailined patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tind will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1) 又	Responsive to communication(s) filed on 23 July 2003.					
2a)□	This action is FINAL . 2b)⊠ This action is non-final.					
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the m					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
4)🖂	Claim(s) <u>1-7</u> is/are pending in the application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)□	Claim(s) is/are allowed.					
6)⊠	Claim(s) 1-7 is/are rejected.					
7)🛛	Claim(s) 7 is/are objected to.					
8)	Claim(s) are subject to restriction and/	or election requirement.				
Applicat	ion Papers					
9)[The specification is objected to by the Examin	er.				
10)⊠ The drawing(s) filed on <u>07/23/2003</u> is/are: a)□ accepted or b)⊠ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority (under 35 U.S.C. § 119					
·	Acknowledgment is made of a claim for foreig)-(d) or (f).			
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
* (See the attached detailed Office action for a lis	, , ,	ad.			
·		it of the certified copies flot receive	Ju.			
		•				
Attachmer		A) [] 1-1	(DTO 442)			
· <u></u>	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948)	4) LI Interview Summary Paper No(s)/Mail Da				
3) Infor	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 or No(s)/Mail Date	5) Notice of Informal P 6) Other:	Patent Application (PTO-152)			

Application/Control Number: 10/625,164 Page 2

Art Unit: 3736

DETAILED ACTION

Priority

1. It is noted that the applicant correctly claimed benefit of a prior-filed application under 35 U.S.C. 119(e).

Information Disclosure Statement

2. The information disclosure statements (IDS) submitted on 10/27/2003 and 03/01/2004 were filed on or after the mailing date of the nonprovisional application on 07/23/2003. The submission is in compliance with the provisions of 37 CFR 1.98. Accordingly, the examiner is considering the information disclosure statements.

Drawings

3. New corrected drawings in compliance with 37 CFR 1.121(d) are required in this application because they are illegible due to darkness. Applicant is advised to employ the services of a competent patent draftsperson outside the Office, as the U.S. Patent and Trademark Office no longer prepares new drawings. The corrected drawings are required in reply to the Office action to avoid abandonment of the application. The requirement for corrected drawings will not be held in abeyance.

Claim Objections

4. Claim 7 is objected to because of the following informalities: reference to "the kit of claim 5" wherein claim 5 is a method. Appropriate correction is required.

Claim Rejections - 35 USC § 112

5. Claim 5 and 7 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim -should refer to other claims in the alternative only-

Application/Control Number: 10/625,164 Page 3

Art Unit: 3736

-. See MPEP § 608.01(n). Accordingly, the claim has not been further treated on the merits.

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 7. Claims 1 and 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Fournier (6155990). Fournier discloses a method for detecting human papilloma virus (HPV) in a vaginal specimen by obtaining a vaginal specimen containing few endocervical cells and using a DNA probe to detect the presence of HPV (column 2 line 65). For claim 4, Fournier also shows the use of obtaining vaginal specimens self-collected by the patient containing few endocervical cells for microbiologic assay for the presence of HPV (column 3, line 3).
- 8. Claim 6 is rejected under 35 U.S.C. 102(b) as being anticipated by Anderson et al (6352513). Anderson et el discloses a kit for self-collection of a vaginal specimen containing few endocervical cells (column 3, line 13) for detection of the presence of HPV (column 1, line 19).

Claim Rejections - 35 USC § 103

- 9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

Art Unit: 3736

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

- 10. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 11. Claims 2 and 3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fournier as applied to claims 1 and 4 above, and further in view of Zavada et al (2003/0049828). Fournier discloses the claimed invention, a method for detecting the presence of HPV in a vaginal specimen by obtaining a self-collected vaginal specimen containing few endocervical cells, except for contacting the vaginal specimen with a polypeptide that binds to a HPV antibody or protein and subsequent detection of the bound antibody or protein in the specimen. Zavada et al teaches assaying body fluid for MN proteins associated with tumorigenicity for diagnosing cancer or precancerous conditions (paragraph 12) and specifically for gynecologic cancers (paragraph 17) using antibodies (paragraph 35) and proteins (paragraph 40) for binding and detecting. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method as taught by Zavada et al, with Fournier since it was

Art Unit: 3736

known in the art that Fournier is used to provide a means for detecting cervical cancerous conditions using antibody and protein binding and detection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey G. Hoekstra whose telephone number is (571)272-7232. The examiner can normally be reached on Monday through Friday, 8:00 a.m. to 5:00 p.m. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Max F. Hindenburg can be reached on (571)272-4726. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JGH

10/18/05

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700